Expectorant Drug Market Report: Trends, Forecast and Competitive Analysis to 2030

Expectorant Drug Market Report: Trends, Forecast and Competitive Analysis to 2030

Expectorant Drug Trends and Forecast

The future of the global expectorant drug market looks promising with opportunities in the hospital pharmacy, retail store, drug store, and online pharmacy markets. The global expectorant drug market is expected to reach an estimated $21.1 billion by 2030 with a CAGR of 4.2% from 2024 to 2030. The major drivers for this market are growing number of incidences of dry cough that lead to dry throats, rising rates of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), as well as, improvements in the performance of expectorant drugs owing to developments and advances in drug formulation and delivery methods.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Expectorant Drug by Segment

The study includes a forecast for the global expectorant drug by drug type, dosage form, product type, distribution channel, and region.

Expectorant Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

• Secretion Enhancer
• Mucolytics

Expectorant Drug Market by Dosage Form [Shipment Analysis by Value from 2018 to 2030]:

• Oral Solid
• Oral Liquid
• Inhalant

Expectorant Drug Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

• Over-The-Counter
• Prescription Drug

Expectorant Drug Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacies
• Retail Store
• Drug Store
• Online Pharmacies
• Others

Expectorant Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Expectorant Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies expectorant drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the expectorant drug companies profiled in this report include-

• Abbott Laboratories
• Acella Pharmaceuticals
• AstraZeneca
• Cipla Limited
• Dabur
• Glenmark Pharmaceuticals
• Johnson and Johnson
• Merck
• Novartis International
• Pfizer

Expectorant Drug Market Insights

Lucintel forecasts that secretion enhancer will remain larger segment over the forecast period due to they are beneficial in the management of several respiratory conditions.

Within this market, retail store will remain the largest segment.

North America will remain the largest region over the forecast period due to growing number of research and development activities, along with government policies and approvals in the region.

Features of the Global Expectorant Drug Market

Market Size Estimates: Expectorant drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Expectorant drug market size by drug type, dosage form, product type, distribution channel, and region in terms of value ($B).

Regional Analysis: Expectorant drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug type, dosage form, product type, distribution channel, and regions for the expectorant drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the expectorant drug market.

Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the expectorant drug market size?

Answer: The global expectorant drug market is expected to reach an estimated $21.1 billion by 2030.

Q2. What is the growth forecast for expectorant drug market?

Answer: The global expectorant drug market is expected to grow with a CAGR of 4.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the expectorant drug market?

Answer: The major drivers for this market are growing number of incidences of dry cough that lead to dry throats, rising rates of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), as well as, improvements in the performance of expectorant drugs owing to developments and advances in drug formulation and delivery methods.

Q4. What are the major segments for expectorant drug market?

Answer: The future of the global expectorant drug market looks promising with opportunities in the hospital pharmacy, retail store, drug store, and online pharmacy markets.

Q5. Who are the key expectorant drug market companies?

Answer: Some of the key expectorant drug companies are as follows:

• Abbott Laboratories
• Acella Pharmaceuticals
• AstraZeneca
• Cipla Limited
• Dabur
• Glenmark Pharmaceuticals
• Johnson and Johnson
• Merck
• Novartis International
• Pfizer

Q6. Which expectorant drug market segment will be the largest in future?

Answer: Lucintel forecasts that secretion enhancer will remain larger segment over the forecast period due to they are beneficial in the management of several respiratory conditions.

Q7. In expectorant drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing number of research and development activities, along with government policies and approvals in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the expectorant drug market by drug type (secretion enhancer and mucolytics), dosage form (oral solid, oral liquid, and inhalant), product type (over-the-counter and prescription drug), distribution channel (hospital pharmacies, retail store, drug store, online pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3. Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6. What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Please note: It will take 2-3 business days to deliver the report upon receipt the order.